# To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

> **NCT07061925** · PHASE2 · COMPLETED · sponsor: **Korea Arlico Pharm. Co., Ltd** · enrollment: 169 (actual)

## Conditions studied

- Acute Bronchitis

## Interventions

- **DRUG:** ALC-2203-1
- **DRUG:** ALC-2203-2
- **DRUG:** ALC-2203-AC
- **DRUG:** Placabo

## Key facts

- **NCT ID:** NCT07061925
- **Lead sponsor:** Korea Arlico Pharm. Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-23
- **Primary completion:** 2025-11-21
- **Final completion:** 2025-11-26
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07061925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07061925, "To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07061925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*